- Home
- ICFI vs AUPH Comparison
ICFI vs AUPH Comparison
Compare ICFI & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICFI
- AUPH
- Stock Information
- Founded
- ICFI 1969
- AUPH 1993
- Country
- ICFI United States
- AUPH Canada
- Employees
- ICFI N/A
- AUPH N/A
- Industry
- ICFI Professional Services
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- ICFI Consumer Discretionary
- AUPH Health Care
- Exchange
- ICFI Nasdaq
- AUPH Nasdaq
- Market Cap
- ICFI 1.7B
- AUPH 1.6B
- IPO Year
- ICFI 2006
- AUPH 1999
- Fundamental
- Price
- ICFI $78.14
- AUPH $15.33
- Analyst Decision
- ICFI Buy
- AUPH Strong Buy
- Analyst Count
- ICFI 4
- AUPH 3
- Target Price
- ICFI $116.75
- AUPH $17.67
- AVG Volume (30 Days)
- ICFI 209.1K
- AUPH 1.9M
- Earning Date
- ICFI 10-30-2025
- AUPH 11-04-2025
- Dividend Yield
- ICFI 0.72%
- AUPH N/A
- EPS Growth
- ICFI N/A
- AUPH N/A
- EPS
- ICFI 5.30
- AUPH 0.55
- Revenue
- ICFI $1,925,502,000.00
- AUPH $265,808,000.00
- Revenue This Year
- ICFI N/A
- AUPH $17.33
- Revenue Next Year
- ICFI $2.61
- AUPH $14.31
- P/E Ratio
- ICFI $14.73
- AUPH $27.90
- Revenue Growth
- ICFI N/A
- AUPH 20.62
- 52 Week Low
- ICFI $72.03
- AUPH $6.55
- 52 Week High
- ICFI $167.55
- AUPH $16.20
- Technical
- Relative Strength Index (RSI)
- ICFI 33.47
- AUPH 71.77
- Support Level
- ICFI $78.50
- AUPH $13.34
- Resistance Level
- ICFI $84.20
- AUPH $15.98
- Average True Range (ATR)
- ICFI 3.33
- AUPH 0.82
- MACD
- ICFI -0.27
- AUPH 0.23
- Stochastic Oscillator
- ICFI 35.11
- AUPH 79.95
About ICFI ICF International Inc.
ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian & Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in a single segment, which is providing professional services.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.